CSBR (Champions Oncology) E10: $-0.24 (As of Jan. 2026)


CSBR Champions Oncology Inc CSBR
64 GF Score
Price $6.14
GF Value $6.62
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology E10?

Champions Oncology CSBR -0.98% 64 E10 is $-0.24 as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Champions Oncology's adjusted earnings per share data for the three months ended in Jan. 2026 was $-0.020. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.24 for the trailing ten years ended in Jan. 2026.

During the past 3 years, the average E10 Growth Rate was 28.30% per year. During the past 5 years, the average E10 Growth Rate was 20.80% per year. During the past 10 years, the average E10 Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Champions Oncology was 28.30% per year. The lowest was -23.10% per year. And the median was 0.70% per year.

As of today (2026-06-25), Champions Oncology's current stock price is $6.14. Champions Oncology's E10 for the quarter that ended in Jan. 2026 was $-0.24. Champions Oncology's Shiller PE Ratio of today is .


Champions Oncology  (NAS:CSBR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Champions Oncology E10 Related Terms


Champions Oncology E10 Historical Data

* Premium members only.

The historical data trend for Champions Oncology's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology E10 Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.16 -0.95 -0.80 -0.69 -0.35

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.35 -0.31 -0.27 -0.24

CSBR vs ANVS, HYFT, GANX: E10 Comparison

For the Biotechnology subindustry, Champions Oncology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Shiller PE Ratio falls into.


CSBR
64GF Score
Champions Oncology Inc CSBR
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Champions Oncology's adjusted earnings per share data for the three months ended in Jan. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jan. 2026 (Change)*Current CPI (Jan. 2026)
=-0.02/325.2520*325.2520
=-0.020

Current CPI (Jan. 2026) = 325.2520.

Champions Oncology Quarterly Data

per share eps CPI Adj_EPS
201604 -0.296 239.261 -0.402
201607 -0.260 240.628 -0.351
201610 -0.050 241.729 -0.067
201701 -0.130 242.839 -0.174
201704 -0.221 244.524 -0.294
201707 -0.060 244.786 -0.080
201710 -0.010 246.663 -0.013
201801 -0.010 247.867 -0.013
201804 -0.060 250.546 -0.078
201807 0.040 252.006 0.052
201810 0.020 252.885 0.026
201901 -0.030 251.712 -0.039
201904 -0.020 255.548 -0.025
201907 -0.060 256.571 -0.076
201910 0.020 257.346 0.025
202001 0.030 257.971 0.038
202004 -0.170 256.389 -0.216
202007 0.010 259.101 0.013
202010 0.000 260.388 0.000
202101 0.070 261.582 0.087
202104 -0.040 267.054 -0.049
202107 -0.010 273.003 -0.012
202110 0.020 276.589 0.024
202201 0.050 281.148 0.058
202204 -0.030 289.109 -0.034
202207 -0.020 296.276 -0.022
202210 -0.001 298.012 -0.001
202301 -0.180 299.170 -0.196
202304 -0.190 303.363 -0.204
202307 -0.190 305.691 -0.202
202310 -0.150 307.671 -0.159
202401 -0.190 308.417 -0.200
202404 -0.010 313.548 -0.010
202407 0.090 314.540 0.093
202410 0.050 315.664 0.052
202501 0.310 317.671 0.317
202504 -0.130 320.795 -0.132
202507 -0.030 323.048 -0.030
202510 0.020 0.000
202601 -0.020 325.252 -0.020

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.24 mean?
Champions Oncology (CSBR) has a E10 of $-0.24 as of Jan. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's E10 too high?
Champions Oncology's current E10 is $-0.24. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's E10 compare to ANVS and HYFT?
Champions Oncology's E10 of $-0.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Champions Oncology and its competitors. Champions Oncology's current E10 is $-0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.14 — trading 7.3% below its estimated fair value. The current E10 is $-0.24. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Champions Oncology (CSBR), the current E10 is $-0.24 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $6.14 is trading 7.3% below its estimated GF Value™ of $6.62. GuruFocus considers Champions Oncology to be Fairly Valued.

Key valuation signals for CSBR:

  • E10: $-0.24
  • GF Value™: $6.62 vs. price of $6.14 (7.3% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score

Get the complete analysis for CSBR

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.14
Price
$6.62
GF Value